- 8.28.2024
- Blog
Navigating Complexity: Reflections on the FDA's MDMA-Assisted Therapy Decision and the Future of Psychedelic Medicine
The FDA’s recent decision to decline approval for MDMA-assisted therapy for PTSD, while disappointing, is not the end of the road. The agency’s request for further research serves as a reminder of the hurdles we still face in advancing psychedelic medicine through regulatory channels.
- 8.14.2024
- News
Microdose: FDA Rejected MDMA-Assisted PTSD Therapy: Psychedelic Industry Responds
Psychedelic industry leaders respond to the FDA's rejection of MDMA-assisted therapy for PTSD, emphasizing the ongoing fight for innovative mental health treatments and the need for new regulatory frameworks.
- 8.10.2024
- News
VETS Stands Firm: Our Response to the FDA's Decision on MDMA-Assisted Therapy
Today, the Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics in response to their application for approval of MDMA-assisted therapy.
- 8.8.2024
- News
The New York Times: Veterans and Lawmakers Lobby in Bipartisan Push for MDMA Therapy
More than a half century after federal regulators banned most psychedelic compounds, the Food and Drug Administration is nearing a decision on a novel treatment for post-traumatic stress disorder that pairs talk therapy with MDMA.
- 8.1.2024
- Blog
My 3rd Re-Birthday: 10 Integration Techniques I Still Practice Daily
Three years ago, on July 31st, 2021 I would sit up out of a bed in Mexico and my life would be changed in the most positive way. Thanks to VETS, I was able to receive a Foundational Healing Grant for psychedelic-assisted therapy treatment with ibogaine and 5MeO-DMT.